Literature DB >> 8473416

Androgen-stimulated pubertal growth: the effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-I in the treatment of short stature and delayed puberty.

B S Keenan1, G E Richards, S W Ponder, J S Dallas, M Nagamani, E R Smith.   

Abstract

The purpose of this study was to investigate the roles of androgenic and estrogenic mechanisms in the stimulation of structural growth and plasma GH in male puberty. To resolve these two possible mechanisms, we compared the effect of two androgens in the treatment of constitutional delay in growth and adolescence: an aromatizable androgen, testosterone (T), and a nonaromatizable androgen, dihydrotestosterone (DHT). Nine adolescent males, Tanner stage 1 or 2, were studied before and during treatment with T enanthate (group A) or DHT heptanoate (group B). After 2.5 months of treatment, the height velocity (HV) was 12.6 +/- 2.8 cm/yr (n = 3) in group A and 8.9 +/- 1.7 cm/yr (n = 6) in group B, both within the range of peak HV for pubertal males. In group A, the integrated concentration of GH (ICGH) increased from 3.12 +/- 0.90 to 13.67 +/- 6.0 micrograms/L (P < 0.05), and plasma insulin-like growth factor-I (IGFI) increased from 126.7 +/- 2.5 to 350.3 +/- 20.3 micrograms/L (P < 0.01); plasma T increased from 0.8 +/- 0.5 to 33.8 +/- 11.0 nmol/L (P < 0.001), and the LH response to LHRH decreased from 27.6 +/- 10.7 to 5.9 +/- 2.5 IU/L (P = NS). In group B, ICGH decreased from 4.32 +/- 0.61 to 2.39 +/- 0.42 (P < 0.025), and IGF-I decreased from 218.3 +/- 39.2 to 184.0 +/- 15.8 (P = NS). Plasma T increased from 2.0 +/- 0.5 to 2.7 +/- 0.8 (P = NS), and the LH response to LHRH decreased from 45.7 +/- 14.5 to 10.7 +/- 5.8 (P < 0.05). To further evaluate the mechanism of the effect of DHT on plasma GH, seven male subjects with adolescent gynecomastia were treated with DHT heptanoate, and their responses were studied at 1 week and 3.5 months. ICGH decreased in conjunction with a decrease in the integrated T concentration (r = -0.77; P < 0.001) and to a slight degree with decreasing plasma estradiol (r = -0.39; P < 0.2). Plasma IGF-I did not show a significant change in the subjects with gynecomastia. Thus, the increase in GH at puberty in males appears to be due to an estrogen-dependent mechanism. The suppressive effect of DHT on GH secretion may be due to either suppression of estradiol production or a direct effect. Acceleration of HV into the peak pubertal range by DHT without an increase in plasma GH suggests that an increase in GH is not necessary for the pubertal growth spurt.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473416     DOI: 10.1210/jcem.76.4.8473416

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  34 in total

Review 1.  Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions.

Authors:  Vanessa Dubois; Michaël Laurent; Steven Boonen; Dirk Vanderschueren; Frank Claessens
Journal:  Cell Mol Life Sci       Date:  2011-11-19       Impact factor: 9.261

Review 2.  Impact of growth plate senescence on catch-up growth and epiphyseal fusion.

Authors:  Ola Nilsson; Jeffrey Baron
Journal:  Pediatr Nephrol       Date:  2005-01-27       Impact factor: 3.714

3.  Determinants of dual secretagogue drive of burst-like growth hormone secretion in premenopausal women studied under a selective estradiol clamp.

Authors:  Dana Erickson; Daniel M Keenan; Leon Farhy; Kristi Mielke; Cyril Y Bowers; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

Review 4.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

5.  The effects of clonidine on blood pressure, catecholamine and growth hormone release in hypogonadal men is preserved and not influenced by testosterone replacement therapy.

Authors:  G Del Rio; C Carani; A Velardo; M Procopio; G Zizzo; P Savio; R Mantovani; P Marrama; E Ghigo
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

6.  Testosterone stimulates growth of tibial epiphyseal growth plate and insulin-like growth factor-1 receptor abundance in hypophysectomized and castrated rats.

Authors:  M Phillip; G Maor; S Assa; A Silbergeld; Y Segev
Journal:  Endocrine       Date:  2001-10       Impact factor: 3.633

Review 7.  Clinical practice. Short stature in childhood--challenges and choices.

Authors:  David B Allen; Leona Cuttler
Journal:  N Engl J Med       Date:  2013-03-28       Impact factor: 91.245

8.  Testosterone supplementation in older men restrains insulin-like growth factor's dose-dependent feedback inhibition of pulsatile growth hormone secretion.

Authors:  Johannes D Veldhuis; Daniel M Keenan; Joy N Bailey; Adenborduin Adeniji; John M Miles; Remberto Paulo; Mihaela Cosma; Cacia Soares-Welch
Journal:  J Clin Endocrinol Metab       Date:  2008-11-04       Impact factor: 5.958

9.  Spuriously Elevated Serum IGF-1 in Adult Individuals with Delayed Puberty: A Diagnostic Pitfall.

Authors:  Syed Ali Imran; Michael Pelkey; David B Clarke; Dale Clayton; Peter Trainer; Shereen Ezzat
Journal:  Int J Endocrinol       Date:  2010-08-30       Impact factor: 3.257

Review 10.  Sexual precocity and its treatment.

Authors:  DeAnna B Brown; Lindsey A Loomba-Albrecht; Andrew A Bremer
Journal:  World J Pediatr       Date:  2013-05-16       Impact factor: 2.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.